Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthtech Industry Analysis

UpdatedAug 12, 2026
DataAggregated Company Financials
Companies68
  • 7D10.4%
  • 3M38.2%
  • 1Y-21.9%
  • YTD-2.4%

In the last week, the Healthtech industry is up 10%, with Veeva Systems up 12%. In the past year, the industry is down 22%. Looking forward, earnings are forecast to grow by 20% annually.

Industry Valuation and Performance

Has the U.S. Healthtech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 12 Aug 2026US$60.1bUS$13.6b-US$357,143,916.0037.1x-168.4x4.4x
Fri, 10 Jul 2026US$51.2bUS$13.8b-US$457,040,179.0034x-112.1x3.7x
Sun, 07 Jun 2026US$47.2bUS$14.4b-US$757,471,326.0030.1x-62.3x3.3x
Tue, 05 May 2026US$47.9bUS$13.6b-US$374,667,415.0031.2x-127.8x3.5x
Thu, 02 Apr 2026US$47.3bUS$13.6b-US$403,014,878.0031.8x-117.3x3.5x
Sat, 28 Feb 2026US$50.0bUS$13.5b-US$343,986,340.0039.1x-145.3x3.7x
Mon, 26 Jan 2026US$62.9bUS$13.6b-US$102,102,340.0051.6x-616.1x4.6x
Wed, 24 Dec 2025US$64.6bUS$13.6b-US$102,572,340.0055.8x-630x4.8x
Fri, 21 Nov 2025US$73.1bUS$13.5b-US$168,353,271.0054.7x-434.2x5.4x
Sun, 19 Oct 2025US$78.5bUS$13.1b-US$211,110,296.0057.4x-371.7x6x
Tue, 16 Sep 2025US$77.9bUS$13.2b-US$266,647,296.0057.7x-292.2x5.9x
Thu, 14 Aug 2025US$75.0bUS$13.1b-US$387,486,382.0058.4x-193.6x5.7x
Sat, 12 Jul 2025US$79.6bUS$13.2b-US$1,382,394,447.0054.8x-57.6x6x
Mon, 09 Jun 2025US$78.7bUS$13.2b-US$1,382,393,022.0057.4x-56.9x5.9x
Wed, 07 May 2025US$71.2bUS$13.2b-US$1,321,731,959.0066.8x-53.9x5.4x
Fri, 04 Apr 2025US$67.5bUS$13.2b-US$1,413,701,089.0050.9x-47.7x5.1x
Sun, 02 Mar 2025US$71.6bUS$13.1b-US$1,576,934,514.0065.7x-45.4x5.5x
Tue, 28 Jan 2025US$69.4bUS$12.9b-US$1,638,054,514.0057.2x-42.4x5.4x
Thu, 26 Dec 2024US$67.3bUS$12.9b-US$1,636,315,514.0055.1x-41.1x5.2x
Sat, 23 Nov 2024US$63.6bUS$12.8b-US$1,712,768,248.0054.3x-37.2x5x
Mon, 21 Oct 2024US$66.3bUS$13.9b-US$3,264,548,151.0054.3x-20.3x4.8x
Wed, 18 Sep 2024US$66.1bUS$14.0b-US$3,302,096,821.0054.7x-20x4.7x
Fri, 16 Aug 2024US$58.8bUS$13.9b-US$3,383,313,571.0051.7x-17.4x4.2x
Sun, 14 Jul 2024US$57.8bUS$13.7b-US$1,860,692,542.0051.8x-31.1x4.2x
Tue, 11 Jun 2024US$58.9bUS$13.7b-US$1,889,950,216.0047.6x-31.2x4.3x
Thu, 09 May 2024US$58.6bUS$12.7b-US$2,026,338,984.0047.2x-28.9x4.6x
Sat, 06 Apr 2024US$61.0bUS$12.7b-US$1,616,515,745.0051.3x-37.7x4.8x
Mon, 04 Mar 2024US$64.0bUS$14.1b-US$1,435,324,794.0050.8x-44.6x4.5x
Wed, 31 Jan 2024US$74.4bUS$18.3b-US$5,780,316,752.0059.9x-12.9x4.1x
Fri, 29 Dec 2023US$72.6bUS$18.3b-US$5,781,192,665.0060.7x-12.6x4x
Sun, 26 Nov 2023US$65.9bUS$18.2b-US$5,807,346,665.0052.5x-11.3x3.6x
Tue, 24 Oct 2023US$67.1bUS$18.0b-US$5,559,240,965.0052.3x-12.1x3.7x
Thu, 21 Sep 2023US$71.1bUS$18.0b-US$5,514,972,389.0050.9x-12.9x3.9x
Sat, 19 Aug 2023US$69.9bUS$17.9b-US$5,552,073,447.0055.2x-12.6x3.9x
Price to Earnings Ratio

-12.6x


Total Market Cap: US$69.9bTotal Earnings: -US$5,552,073,447.00Total Revenue: US$17.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthtech Industry Price to Earnings3Y Average -136.3x202420252026
Current Industry PE
  • Investors are relatively neutral on the American Healthcare Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Healthcare Services industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 8.7% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.091%
Healthcare3.58%
Healthtech10.39%
Healthtech10.39%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VEEV Veeva SystemsUS$236.5811.7%
+US$4.0b		-14.1%PE40.8x
DOCS DoximityUS$26.1119.3%
+US$719.2m		-57.8%PE27.9x
SDGR SchrödingerUS$18.6519.2%
+US$225.7m		-1.1%PS5.4x
HTFL HeartFlowUS$29.548.3%
+US$194.9m		-1.2%PS13.3x
GDRX GoodRx HoldingsUS$3.8013.8%
+US$165.2m		8.6%PE79.8x

Latest News

GDRX
US$3.80
GoodRx Holdings
7D
13.8%
1Y
8.6%
Seeking Alpha • 5h

GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope

Summary GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating. Despite operational progress, risk-reward remains balanced at current valuations, justifying a cautious stance. Read the full article on Seeking Alpha
AIFF
US$1.14
Firefly Neuroscience
7D
-4.2%
1Y
-59.0%
DH
US$0.64
Definitive Healthcare
7D
-8.0%
1Y
-82.1%
HTFL
US$29.54
HeartFlow
7D
8.3%
1Y
-1.2%
CCLD
US$2.44
CareCloud
7D
-6.2%
1Y
-3.6%
Analysis Article • Aug 09

CareCloud, Inc. (NASDAQ:CCLD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

It's been a good week for CareCloud, Inc. ( NASDAQ:CCLD ) shareholders, because the company has just released its...
SDGR
US$18.65
Schrödinger
7D
19.2%
1Y
-1.1%
CTEV
US$34.96
Claritev
7D
32.4%
1Y
-46.8%
DOCS
US$26.11
Doximity
7D
19.3%
1Y
-57.8%
Narrative Update • Aug 08

DOCS: AI Investment Year And Pharma Budget Share Will Shape Fairly Valued Outlook

Analysts have raised Doximity’s fair value estimate from $24.37 to $28.00, reflecting Street research that highlights solid recent results, early traction in AI search, and the potential for the company to capture a larger share of pharma marketing budgets, despite ongoing questions about competition and execution risk. Analyst Commentary Street research on Doximity is split, with some bullish analysts pointing to improving execution and AI traction, while more cautious voices focus on execution risk, competition in healthcare AI, and visibility on longer term growth.
LFMD
US$3.38
LifeMD
7D
-13.3%
1Y
-50.5%
Narrative Update • Aug 08

LFMD: Higher Investment Now Will Support Stronger Margins And Earnings Multiple

Analysts have reduced the LifeMD price target from $8.00 to $5.00, aligning with recent Street revisions that highlight softer near term guidance alongside higher investment spending, as well as improved profit margin expectations and a lower future P/E assumption. Analyst Commentary Recent Street commentary on LifeMD reflects a more cautious stance, with several bearish analysts trimming price targets and highlighting execution and growth risks following the latest Q2 update and guidance reset.
HCAT
US$1.76
Health Catalyst
7D
-22.8%
1Y
-41.3%
EVH
US$4.10
Evolent Health
7D
31.8%
1Y
-53.4%
WAY
US$24.30
Waystar Holding
7D
2.2%
1Y
-29.7%
Narrative Update • Aug 07

WAY: Payment Software Adoption And New CFO Leadership May Support Future Upside

Analysts have nudged their fair value estimate for Waystar Holding from $25.00 to $27.00 as they refine assumptions around revenue growth, profit margins, and future P/E expectations. What’s in the News for Waystar Holding Waystar Holding appointed Alpana Wegner as Chief Financial Officer, effective August 1, 2026, succeeding long serving CFO Steve Oreskovich.
HSTM
US$28.36
HealthStream
7D
-4.8%
1Y
6.9%
VEEV
US$236.58
Veeva Systems
7D
11.7%
1Y
-14.1%
SLP
US$18.31
Simulations Plus
7D
-0.2%
1Y
29.1%
Seeking Alpha • Jul 19

Simulations Plus: The Potential Little Spread Is Not Worth The Risk For New Money, Hold

Summary Simulations Plus reported a strong 7% revenue growth during the quarter, while its net income improved to $3.6 million. Simulation and Altaris have agreed to a buyout agreement wherein the latter will pay $18.5 per share in an all-cash deal, valuing Simulation at $375 million. The meager difference between the current stock price ($18.23) and the deal price ($18.5) reflects merger-arbitrage situation. I rate SLP a Hold. Existing holders can squeeze in more gain as the deal gets closer to completion. For Newcomers, the little upside is not enticing enough to warrant a fresh position, given potential risks associated with the impedingdeal. Read the full article on Seeking Alpha
BFRG
US$0.58
Bullfrog AI Holdings
7D
-5.3%
1Y
-54.3%